Advertisement

Role of D1 receptor mechanisms in the potentiation of motor responses to L-DOPA and apomorphine by MK 801 in the reserpine-treated mouse

  • S. Kaur
  • M. S. Starr
  • B. S. Starr
Full Papers

Summary

In 24 h reserpine-treated akinetic mice, locomotion was induced by the D1-selective agonist SKF 38393 (30 mg/kg IP), or by the mixed D1/D2 agonists L-DOPA (150 mg/kg IP, plus benserazide 100 mg/kg IP) and apomorphine (0.5 mg/kg SC). The non-competitive NMDA receptor antagonist MK 801 (0.01–1.6 mg/kg IP) did not induce motor activity by itself, but potentiated the motor responses to L-DOPA and apomorphine at roughly 10-fold lower doses than those which facilitated D1 responding. These data cast doubt on the notion that glutamate antagonists enhance the antiparkinsonian efficacy of mixed D1/D2 agonists solely through a D1 receptor mechanism.

Key words

Mouse reserpine locomotion MK 801 SKF 38393 L-DOPA apomorphine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436–1438PubMedGoogle Scholar
  2. Boldry RC, Chase TN, Engber TM (1993) Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions. J Pharmacol Exp Ther 267: 1454–1459PubMedGoogle Scholar
  3. Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR (1991) Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 6: 133–138CrossRefPubMedGoogle Scholar
  4. Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221–226CrossRefPubMedGoogle Scholar
  5. Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272–276CrossRefPubMedGoogle Scholar
  6. Carlsson M, Svensson A (1990) The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice. Life Sci 47: 1729–1736CrossRefPubMedGoogle Scholar
  7. Clark D, White FJ (1987) D1 dopamine receptor — The search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1: 347–388CrossRefPubMedGoogle Scholar
  8. Coleman RJ (1992) Current drug therapy for Parkinson's disease. Drugs and Aging 2: 112–124PubMedGoogle Scholar
  9. Crossman AR, Mitchell IJ, Brotchie JM, Aziz TZ, Graham WC, Robertson R, Sambrook MA (1992) Excitatory amino acid transmission of subthalamic nucleus efferents: relationship to hyperkinetic movement disorders and to parkinsonism. In: Simon RP (ed) Excitatory amino acids. Thieme, New York, pp 199–202Google Scholar
  10. Domino EF, Sheng J (1993) N-Methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 264: 221–225PubMedGoogle Scholar
  11. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamine (3-hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38: 1236–1239CrossRefPubMedGoogle Scholar
  12. Engber TM, Anderson JJ, Boldry RC, Papa SM, Kuo S, Chase TN (1994) Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats. Neuroscience 59: 389–399CrossRefPubMedGoogle Scholar
  13. Gandolfi O, Rimondini R, Dall'Olio R (1992) The modulation of dopaminergic transmission in the striatum by MK-801 is independent of presynaptic mechanisms. Neuropharmacology 31: 1111–1114CrossRefPubMedGoogle Scholar
  14. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley DR (1991) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429–1432Google Scholar
  15. Goodwin P, Starr BS, Starr MS (1992) Motor responses to dopamine D1 and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK 801. J Neural Transm [PD Sect] 4: 15–26Google Scholar
  16. Greenamayre JT (1993) Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm [Gen Sect] 91: 255–269CrossRefGoogle Scholar
  17. Kannari K, Markstein R (1991) Dopamine agonists potentiate antiakinetic effects of competitive NMDA-antagonists in monoamine-depleted mice. J Neural Transm [Gen Sect] 84: 211–220CrossRefGoogle Scholar
  18. Klockgether T, Turski L (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 21: 285–286CrossRefGoogle Scholar
  19. Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 28: 539–546CrossRefPubMedGoogle Scholar
  20. Klockgether T, Turski L, Honore T, Zhang Z, Gash DM, Kurlan R, Greenamayre JT (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine depleted rats and MPTP treated monkeys. Ann Neurol 30: 717–723CrossRefPubMedGoogle Scholar
  21. Klockgether T, Turski L, Löschmann PA, Wachtel H (1990) N-methyl-D-aspartate antagonists stimulate motor activity in monoamine depleted rats: implications for the therapy of Parkinson's disease. In: Lubec G, Rosenthal GA (eds) Amino acids: chemistry, biology and medicine. Leiden, pp 269–275Google Scholar
  22. Komori K, Uesaka S, Yamaoka H, Fujita K, Yamaoka K, Naitoh H, Kuroda M, Karasawa N, Ito T, Kasahara Y, Nagatsu I (1993) Identification of L-DOPA immunoreactivity in some neurons in the human mesencephalic region: a novel DOPA neuron group? Neurosci Lett 157: 13–16CrossRefPubMedGoogle Scholar
  23. Kopin IJ (1993) The pharmacology of Parkinson's disease therapy: an update. Ann Rev Pharmacol Toxicol 32: 467–495Google Scholar
  24. Löschmann PA, Lange KW, Kunow M, Rettig KJ, Jähnig P, Honore Turski T, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. J Neural Transm [PD Sect] 3: 203–213Google Scholar
  25. Luquin MR, Obeso JA, Laguna J, Guillen J, Martinez-Lage JM (1993) The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur J Pharmacol 235: 297–300CrossRefPubMedGoogle Scholar
  26. Maj J, Skuza G, Rogoz Z (1993) Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. J Neural Transm [PD Sect] 6: 53–62Google Scholar
  27. Miller WC, DeLong MR (1987) Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayaraman A (eds) The basal ganglia II. Plenum Press, New York, pp 415–427Google Scholar
  28. Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR (1989) Neural mechanisms underlying parkinsonian symtpoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32: 213–226CrossRefPubMedGoogle Scholar
  29. Morelli M, Di Chiara G (1990) MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur J Pharmacol 182: 611–612CrossRefPubMedGoogle Scholar
  30. Morelli M, Fenu S, Pinna A, Di Chiara G (1992) Opposite effects of NMDA blockade on dopaminergic D1- and D2-mediated behaviour in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J Pharmacol Exp Ther 290: 402–408Google Scholar
  31. Paul ML, Graybiel AM, David J-C, Robertson HA (1992) D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J Neurosci 12: 3729–3742PubMedGoogle Scholar
  32. Riederer P, Lange KW, Youdim MB (1993) Recent advances in pharmacological therapy of Parkinson's disease. Adv Neurol 60: 626–635PubMedGoogle Scholar
  33. Schmidt WJ, Bubser M, Hauber W (1992) Behavioural pharmacology of glutamate in the basal ganglia. J Neural Transm [Suppl] 38: 65–89Google Scholar
  34. Setler PE, Sarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50: 419–430CrossRefPubMedGoogle Scholar
  35. Starr MS, Starr BS (1993a) Facilitation of dopamine D1 receptor-but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treatd mouse. Eur J Pharmacol 250: 239–246CrossRefPubMedGoogle Scholar
  36. Starr MS, Starr BS (1993b) Glutamate antagonists modify the motor stimulant actions of D1 and D2 agonists in reserpine-treated mice in complex ways that are not predictive of their interactions with the mixed D1/D2 agonist apomorphine. J Neural Transm [PD Sect] 6: 215–226Google Scholar
  37. Starr MS, Starr BS (1994) Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpinetreated mice. Psychopharmacology 114: 469–476CrossRefPubMedGoogle Scholar
  38. Starr BS, Starr MS, Kilpatrick IC (1987) Behavioural role of dopamine D1 receptors in the reserpine-treated mouse. Neuroscience 22: 179–187CrossRefPubMedGoogle Scholar
  39. Svensson A, Carlsson A, Carlsson ML (1992) Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice. J Neural Transm [Gen Sect] 90: 199–217CrossRefGoogle Scholar
  40. Turski L, Schwarz M, Turski WA, Klockgether T, Sontag K-H, Collins JF (1985) Muscle relaxant action of excitatory amino acid antagonists. Neursci Lett 53: 321–326CrossRefGoogle Scholar
  41. Verma A, Kulkarni SK (1992) Modulation of MK-801 response by dopaminergic agents in mcie. Psychopharmacology 107: 431–436PubMedGoogle Scholar
  42. Wachtel H, Kunow M, Löschmann PA (1992) NBQX (6-nitro-sulfamoyl-benzoquinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neurosci Lett 142: 179–182CrossRefPubMedGoogle Scholar
  43. Whitton PS, Biggs CS, Pearce BS, Fowler LJ (1992) Regional effects of MK-801 on dopamine and its metabolites studies by in vivo microdialysis. Neurosci Lett 142: 5–8CrossRefPubMedGoogle Scholar
  44. Wüllner U, Kupsch A, Arnold G, Renner P, Scheid C, Scheid R, Oertel W, Klockgether T (1992) The competitive NMDA antagonist CGP 40116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology 31: 713–715CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • S. Kaur
    • 1
  • M. S. Starr
    • 2
  • B. S. Starr
    • 2
  1. 1.Department of PharmacologySchool of PharmacyLondonUK
  2. 2.Psychology Division, School of Health and Human SciencesUniversity of HertfordshireHatfieldUK

Personalised recommendations